BACKGROUND AND OBJECTIVES: Hispanics are the largest minority group in the United States. The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease (CVD), yet little is known about its prevalence among Hispanics with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted cross-sectional analyses of prevalent self-reported clinical and subclinical measures of CVD among 497 Hispanics, 1638 non-Hispanic Caucasians, and 1650 non-Hispanic African Americans, aged 21 to 74 years, with mild-to-moderate CKD at enrollment in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic CRIC (HCRIC) studies. Measures of subclinical CVD included left ventricular hypertrophy (LVH), coronary artery calcification (CAC), and ankle-brachial index. RESULTS: Self-reported coronary heart disease (CHD) was lower in Hispanics compared with non-Hispanic Caucasians (18% versus 23%, P = 0.02). Compared with non-Hispanic Caucasians, Hispanics had a lower prevalence of CAC >100 (41% versus 34%, P = 0.03) and CAC >400 (26% versus 19%, P = 0.02). However, after adjusting for sociodemographic factors, these differences were no longer significant. In adjusted analyses, Hispanics had a higher odds of LVH compared with non-Hispanic Caucasians (odds ratio 1.97, 95% confidence interval, 1.22 to 3.17, P = 0.005), and a higher odds of CAC >400 compared with non-Hispanic African Americans (odds ratio, 2.49, 95% confidence interval, 1.11 to 5.58, P = 0.03). Hispanic ethnicity was not independently associated with any other CVD measures. CONCLUSIONS: Prevalent LVH was more common among Hispanics than non-Hispanic Caucasians, and elevated CAC score was more common among Hispanics than non-Hispanic African Americans. Understanding reasons for these racial/ethnic differences and their association with long-term clinical outcomes is needed.
BACKGROUND AND OBJECTIVES: Hispanics are the largest minority group in the United States. The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease (CVD), yet little is known about its prevalence among Hispanics with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted cross-sectional analyses of prevalent self-reported clinical and subclinical measures of CVD among 497 Hispanics, 1638 non-Hispanic Caucasians, and 1650 non-Hispanic African Americans, aged 21 to 74 years, with mild-to-moderate CKD at enrollment in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic CRIC (HCRIC) studies. Measures of subclinical CVD included left ventricular hypertrophy (LVH), coronary artery calcification (CAC), and ankle-brachial index. RESULTS: Self-reported coronary heart disease (CHD) was lower in Hispanics compared with non-Hispanic Caucasians (18% versus 23%, P = 0.02). Compared with non-Hispanic Caucasians, Hispanics had a lower prevalence of CAC >100 (41% versus 34%, P = 0.03) and CAC >400 (26% versus 19%, P = 0.02). However, after adjusting for sociodemographic factors, these differences were no longer significant. In adjusted analyses, Hispanics had a higher odds of LVH compared with non-Hispanic Caucasians (odds ratio 1.97, 95% confidence interval, 1.22 to 3.17, P = 0.005), and a higher odds of CAC >400 compared with non-Hispanic African Americans (odds ratio, 2.49, 95% confidence interval, 1.11 to 5.58, P = 0.03). Hispanic ethnicity was not independently associated with any other CVD measures. CONCLUSIONS: Prevalent LVH was more common among Hispanics than non-Hispanic Caucasians, and elevated CAC score was more common among Hispanics than non-Hispanic African Americans. Understanding reasons for these racial/ethnic differences and their association with long-term clinical outcomes is needed.
Authors: Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: Carlos J Rodriguez; Robert R Sciacca; Ana V Diez-Roux; Bernadette Boden-Albala; Ralph L Sacco; Shunichi Homma; Marco R DiTullio Journal: Hypertension Date: 2004-02-23 Impact factor: 10.190
Authors: Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Faraz S Ahmad; Xuan Cai; Katherine Kunkel; Ana C Ricardo; James P Lash; Dominic S Raj; Jiang He; Amanda H Anderson; Matthew J Budoff; Julie A Wright Nunes; Jason Roy; Jackson T Wright; Alan S Go; Martin G St John Sutton; John W Kusek; Tamara Isakova; Myles Wolf; Martin G Keane Journal: Am J Hypertens Date: 2017-08-01 Impact factor: 2.689
Authors: Michael J Fischer; Jesse Y Hsu; Claudia M Lora; Ana C Ricardo; Amanda H Anderson; Lydia Bazzano; Magdalena M Cuevas; Chi-Yuan Hsu; John W Kusek; Amada Renteria; Akinlolu O Ojo; Dominic S Raj; Sylvia E Rosas; Qiang Pan; Kristine Yaffe; Alan S Go; James P Lash Journal: J Am Soc Nephrol Date: 2016-05-05 Impact factor: 10.121
Authors: Cristina M Arce; Aya A Mitani; Benjamin A Goldstein; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2011-11-23 Impact factor: 8.237
Authors: Meyeon Park; Chi-yuan Hsu; Yongmei Li; Rakesh K Mishra; Martin Keane; Sylvia E Rosas; Daniel Dries; Dawei Xie; Jing Chen; Jiang He; Amanda Anderson; Alan S Go; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2012-08-30 Impact factor: 10.121
Authors: Benjamin A Goldstein; Cristina M Arce; Mark A Hlatky; Mintu Turakhia; Soko Setoguchi; Wolfgang C Winkelmayer Journal: Circulation Date: 2012-10-02 Impact factor: 29.690
Authors: Ernesto Paoletti; Luca De Nicola; Francis B Gabbai; Paolo Chiodini; Maura Ravera; Laura Pieracci; Sonia Marre; Paolo Cassottana; Sergio Lucà; Simone Vettoretti; Silvio Borrelli; Giuseppe Conte; Roberto Minutolo Journal: Clin J Am Soc Nephrol Date: 2015-12-14 Impact factor: 8.237